Taurine Cognition Randomized Trial: What the Evidence Says

Quick Answer

Taurine Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Cirrhosis is a major and growing global cause of morbidity and premature mortality, driven largely by alcohol-associated liver disease and metabolic dysfunction-associated steatotic liver disease alongside chronic viral hepatitis. [Sasidharan Swarup (2026); evidence level 2]
• Fatigue in chronic liver disease is a multidimensional syndrome involving reduced physical and mental energy, impaired motivation, reduced endurance, and slowed cognition that is often poorly relieved by rest. [Sasidharan Swarup (2026); evidence level 2]
• As life expectancy increases, age-associated declines in muscle strength, metabolic flexibility, immune responsiveness, and cognitive resilience have become major contributors to morbidity and diminished quality of life. [Chen Zhigang (2026); evidence level 3]
• Despite these benefits, the biological response to exercise is often dampened in aging due to reduced mitochondrial efficiency, lower anabolic sensitivity, impaired antioxidant capacity, and chronic inflammatory signaling. [Chen Zhigang (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For taurine cognition randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Sasidharan Swarup (2026). A randomized controlled trial of L -taurine for fatigue in decompensated cirrhosis. DOI: 10.1097/HC9.0000000000000938. PMCID: PMC13120592. PMID: 42043864. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution-Non Commercial-No Derivatives License.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13120592/
• Chen Zhigang (2026). Taurine and glutamine supplementation in aging: systemic mechanisms, exercise interactions, and modulation of muscular and neurobiological pathways. DOI: 10.3389/fphys.2026.1809107. PMCID: PMC13180548. PMID: 42158500. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13180548/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.